Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
Management will engage in a fireside chat on September 10th at 1:05 PM ET. Investors can access both live and archived webcasts of the presentation through the company's website investor section at adaptivebiotech.com.
Positive
- None.
Negative
- None.
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, September 10th at 10:05 a.m. Pacific Time / 1:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
FAQ
When is Adaptive Biotechnologies (ADPT) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors watch Adaptive Biotechnologies' Morgan Stanley conference presentation?
What type of presentation will Adaptive Biotechnologies (ADPT) give at the Morgan Stanley conference?
What is Adaptive Biotechnologies' main business focus?
